Editorial Notes
References in Text

Schedules III, IV, and V, referred to in subsec. (a)(2), are set out in section 812(c) of this title.

Section 3204(b) of the SUPPORT for Patients and Communities Act, referred to in subsec. (b)(2), is section 3204(b) of Pub. L. 115–271, title III, Oct. 24, 2018, 132 Stat. 3946, which is not classified to the Code.

Amendments

2025—Subsec. (a)(2). Pub. L. 119–26, § 4(2)(B)(iii), amended Pub. L. 117–328, § 1262(b)(2). See 2022 Amendment note below.

2022—Subsec. (a)(2). Pub. L. 117–328, § 1262(b)(2), as amended by Pub. L. 119–26, § 4(2)(B)(iii), substituted “the controlled substance is a narcotic drug in schedule III, IV, or V to be administered for the purpose of maintenance or detoxification treatment and is to be administered by injection or implantation;” for “the controlled substance is to be administered for the purpose of maintenance or detoxification treatment under section 823(g)(2) and—”

“(A) the practitioner who issued the prescription is a qualifying practitioner authorized under, and acting within the scope of that section; and

“(B) the controlled substance is to be administered by injection or implantation;”.

Pub. L. 117–215 substituted “823(h)(2)” for “823(g)(2)” in introductory provisions.

Subsec. (a)(5). Pub. L. 117–328, § 1264, substituted “45 days” for “14 days”.

Statutory Notes and Related Subsidiaries
Effective Date of 2025 Amendment

Pub. L. 119–26, § 4, July 16, 2025, 139 Stat. 416, provided that the amendment made by section 4(2)(B)(iii) is effective as if included in the enactment of Pub. L. 117–328.